HeartCycle

HeartCycle consortium, comprising 18 research, academic, industrial and medical organizations from 9 different European countries and China, will work to improve the quality of life for coronary heart disease and heart failure patients by monitoring their condition and involving them in the daily management of their disease. The consortium will also develop mechanisms to automatically report relevant monitoring data back to clinicians so that they can prescribe personalized therapies and lifestyle recommendations.

Compliance to prescribed therapies is a common problem associated with long-term treatment, and will become even more problematic as the European population ages and chronic disease becomes more prevalent. There is strong evidence that increasing the level of patient compliance may have a far greater impact on the health of the population than improvements in specific medical treatments. The HeartCycle project intends to tackle this in two ways.

Firstly by creating a 'patient loop' that gives patients continuous feedback on their state of health, their progress towards achieving health status milestones, plus motivational tips and suggestions for a healthy lifestyle and diet. In the course of the project it will be investigated whether such measures will improve the adherence to prescribed therapies. Monitoring each patient's condition will be achieved using a combination of unobtrusive bio-sensors built into the patient's clothing or bed sheets and home appliances such as weighing scales and blood pressure monitors. Sensing of an individual patient's physical exertion, body orientation and ambient environment will provide additional information so that the system can put the monitoring data into context.

Secondly by enabling a 'professional loop' in which relevant data on a patient’s state of health and therapy adherence is automatically communicated to a hospital information system. This professional loop will allow doctors to monitor each patient's condition and therapy response in order to create optimized individual care plans, as well as allowing them to identify deterioration or sudden cardiac events that require immediate remedial action.

For further information, please visit:
http://www.heartcycle.eu

Project co-ordinator:
Philips Research

Partners:

  • Aristotle University of Thessaloniki (Greece);
  • Clothing Plus Oy (Finland);
  • CSEM Centre Suisse D'electronique Et De Microtechnique Sa (Switzerland);
  • Empirica Gesellschaft für Kommunikations und Technologieforschung mbH (Germany);
  • Faculdade Ciencias e Tecnologia da Universidade de Coimbra (Portugal);
  • Fundación Vodafone España (Spain);
  • Hospital Universitario Clínico San Carlos (Spain);
  • Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (Spain);
  • Medtronic Ibérica SA (Spain);
  • Philips Electronics Nederland B.V. (The Netherlands);
  • Philips Research (Germany);
  • Politecnico Di Milano - Dipartimento di Bioingegneria (Italy);
  • Rheinisch Westfälische Technische Hochschule (Germany);
  • T-Systems ITC Iberia SA (Spain);
  • Universidad Politécnica de Madrid (Spain);
  • Chinese University of Hong Kong (China);
  • University of Hull (United Kingdom);
  • Valtion Teknillinen Tutkimuskeskus (Finland).

Timetable: from 03/2008 – to 02/2012

Total cost: € 21.985.444

EC funding: € 14.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics

Contract type: Collaborative project (generic)


Related news articles:

Most Popular Now

Merck and Tencent Announce Collaboration…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public...

Merck Granted U.S. Patent for Novel Comb…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO). The patent relates...

The European Health Catapult Program for…

Through dedicated sessions, a group of international top-level investors, key healthcare leaders and industry stakeholders work closely together challenging 40+ ambitious startups to optimize their business plan and strengthen their...

Applications Now Open for Pioneering Dig…

The Yorkshire & Humber AHSN (Academic Health Science Network), in partnership with mHabitat, announces that applications for the 2019 Propel@YH digital health accelerator programme are now open. Propel@YH has been...

Flagship Axe the Fax Trust Rolls out Hyb…

Leeds Teaching Hospitals NHS Trust (LTHT), the organisation at the forefront of the national Axe the Fax campaign, is implementing an electronic fax solution to tackle its last remaining machines...

First EU Citizens Using ePrescriptions i…

The first EU patients can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country: Finnish patients are now able to go to a...

Boehringer Ingelheim (Canada) Ltd. and I…

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology...

Final Report: Provision of a Market Stud…

The aim of the study is to examine the telemedicine market in Europe and to understand the factors that determine its development. The analysis maps telemedicine applications and solutions, and...

Open Access Drug Development Tools Featu…

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of...

The NHS Long Term Plan: Cracking the Da …

Opinion Article by Prof. Michael Thick, Chief Medical Officer, Chief Clinical Information Officer, IMS MAXIMS Reading the NHS Long Term Plan this week, I had a definite sense of déjà vu...

Big Data Approach Shown to be Effective …

Researchers at Rensselaer Polytechnic Institute who developed a blood test to help diagnose autism spectrum disorder have now successfully applied their distinctive big data-based approach to evaluating possible treatments. The...

Highland Marketing Advisory Board Respon…

The first meeting of Highland Marketing's newly expanded advisory board discussed the NHS Long Term Plan and what will be needed to make it a success. Structural change, leadership, investment...